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ABSTRACT 94 
Brain malformations involving the corpus callosum are common in children with developmental 95 
disabilities. We report that DCC mutations cause isolated agenesis of the corpus callosum (ACC), 96 
without intellectual disability, in four families and five sporadic individuals. DCC mutations 97 
result in variable dominant phenotypes with reduced penetrance including mirror movements and 98 
ACC associated with a favorable developmental prognosis. Possible phenotype modifiers include 99 
the type and location of mutation and sex of the individual. 100 
 101 
MAIN TEXT 102 
The corpus callosum (CC) is the main cerebral commissure in placental mammals with a key role 103 
in communication between the brain hemispheres1. Formation of the CC is a complex process 104 
involving ligands such as those in the Netrin, Ephrin, Semaphorin and Slit families and their 105 
receptors2. Agenesis of the corpus callosum (ACC) is the complete or partial absence of the CC. 106 
This frequent brain malformation affects ~1/4,000 newborns and 3-5% of children with 107 
intellectual disability (ID)3,4 and is a common cause of late pregnancy termination5. Mutations in 108 
many genes cause syndromes with ID and ACC, whereas the genetics of isolated ACC remain 109 
poorly understood3,6,7. The Netrin receptor Dcc plays a critical role in CC development in mice 110 
by guiding callosal axons at the midline8. While mutations in DCC have been associated with 111 
congenital mirror movements (MM) in humans9, they have not been described in individuals with 112 
ACC. 113 
 114 
We investigated four multigenerational families with individuals presenting with ACC, MM or 115 
both phenotypes segregating as autosomal dominant traits (Fig. 1a). Neuroimaging and clinical 116 
studies confirmed that complete or partial ACC was isolated in most cases (Fig. 1b, Fig. S1) and 117 
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associated with a range of intellectual abilities (normal-borderline impaired); additionally, 118 
specific cognitive impairments, including language delay or visuospatial deficits, were 119 
documented (Table S1). Diffusion MRI tractography using probabilistic constrained spherical 120 
deconvolution identified reduced crossing of descending corticospinal tract projections at the 121 
pyramidal decussation in all affected individuals in families 2 and 4 with either ACC and MM 122 
(n=5) or MM only (n=2) (Fig. 1c, Fig. S2). The tractography results for other commissural fibers, 123 
including the decussation of the superior cerebellar peduncles, anterior commissure, posterior 124 
commissure and optic chiasm, were comparable between the affected individuals and controls. 125 
 126 
Linkage analysis and exome sequencing of three affected individuals in family 1 identified two 127 
shared candidate variants in the 16 linkage regions (Fig. S3, Table S2) including a truncating 128 
mutation in DCC (NM_005215.3:c.925delA, p.(Thr309ProfsTer26)). For family 2, 48 candidate 129 
variants were identified in 28 linkage regions (Fig. S4, Table S3), including a missense variant 130 
(c.2378T>G, p.(Val793Gly)) in DCC. The previously-reported nonsense mutation (c.823C>T, 131 
p.(Arg275Ter)) in DCC segregated with MM in five individuals of family 310. Further 132 
investigation revealed two additional female mutation carriers with ACC and a male carrier with 133 
MM who had a thin rostrum. Direct screening in family 4 identified a heterozygous DCC 134 
missense variant (c.2414G>A, p.(Gly805Glu)). All four DCC mutations were absent from public 135 
databases, including 1000 Genomes and ExAC, and segregated with ACC and/or MM in all 136 
available individuals tested (Fig. 1a). In addition, we sequenced DCC in 70 unrelated individuals 137 
with ACC including 46 with normal cognitive development. Five individuals, all with isolated 138 
complete ACC, had at least one heterozygous missense variant altering a conserved amino acid of 139 
DCC (Fig. 1d, Fig. S1 and S5, Table 1). Analysis of all available imaging in mutation-positive 140 
individuals with complete ACC also showed absence of the hippocampal commissure and 141 
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cingulate gyri, and dysmorphic lateral ventricles (usually colpocephaly) as would be expected 142 
(detailed in Online  methods). Apart from this, no consistent additional brain malformations were 143 
seen. 144 
 145 
We analyzed the phenotype of individuals with DCC mutations reported in the literature and in 146 
this study (Table S4) to assess the penetrance of MM and ACC. Of the 88 individuals with DCC 147 
mutations identified to date, 50 had MM; among the 39 who had brain imaging, 19 exhibited 148 
ACC. Excluding the index individuals from the analysis, the penetrance of MM was estimated to 149 
be 42% and the penetrance of ACC to be 26% (Table S5). Overall, males (n=31) exhibited MM 150 
more frequently than females (n=19, male:female ratio=1.8, p=0.0027, Fisher’s Exact test; Table 151 
S5) while, in individuals with truncating DCC variants, ACC was more often present in females 152 
(n=7) than males (n=1, male:female ratio=0.2). Sex differences in CC anatomy have been 153 
associated with testosterone levels during prenatal brain development11-13; therefore, we tested 154 
the effect of androgens on DCC expression. Independent analysis by RNAseq and RT-qPCR 155 
demonstrated a significant dose-dependent increase in DCC expression in human neural stem 156 
cells treated with 10 nM or 100 nM testosterone (Fig. S6). Since variants introducing a premature 157 
stop codon generally result in haploinsufficiency due to nonsense mediated decay of the mutant 158 
mRNA, it is possible that ACC may occur when the amount of DCC mRNA/protein falls below a 159 
threshold level during CC development, which would occur more frequently in females. 160 
However, given the incomplete penetrance observed in both sexes, the phenotypic outcome must 161 
also be influenced by additional genetic, epigenetic and/or environmental factors. Interestingly, 162 
families 1 and 3, in which a majority of females display ACC, are both of North African 163 
background, supporting the hypothesis of genetic modifiers.  164 
 165 
 - 7 - 
Contrary to truncating variants, missense mutant proteins are usually present in the cell and can 166 
interfere with the function of the wildtype protein, potentially resulting in differing phenotypes 167 
compared to haploinsufficiency for the same protein. Binding of Netrin-1 to DCC results in 168 
intracellular homodimerization or heterodimerization with UNC5, another axon guidance 169 
receptor, and is critical for both the chemoattractive and chemorepulsive properties of the 170 
signaling complexes15,16. The Netrin-1 binding region involves the 4th, 5th and 6th fibronectin 171 
type III-like domains of DCC14,15, therefore amino acid substitutions in this binding region may 172 
compromise DCC function. Five of the eight DCC missense variants identified in individuals 173 
with ACC are located in the Netrin-1 binding region (Fig. 1d), which represents a considerable 174 
enrichment compared to missense variants located in this domain in ExAC (5/74, 6.7% versus 175 
519/~60000, 0.86%; p=5x10-4 (all rare variants) or 284/~60000, 0.47%; p=3x10-5 (rare variants 176 
predicted to be damaging by SIFT), Fisher’s exact test (Table S6)). Given the reduced penetrance 177 
and mild phenotype of DCC-related ACC, it is possible that some individuals described in ExAC 178 
have pathogenic DCC mutations and undiagnosed ACC. 179 
 180 
Modelling of DCC missense variants revealed that the amino acid substitutions in families 2 and 181 
4, both located within the DCC/Netrin-1 binding interface, are predicted to be most disruptive. 182 
The p.(Val793Gly) substitution abolishes a hydrophobic interaction with Thr147 of Netrin-1 183 
while p.(Gly805Glu) introduces a highly unfavorable charged moiety within a hydrophobic 184 
pocket, disrupting interaction with Leu113 of Netrin-1 (Fig. S7-8). The predicted effects of the 185 
three substitutions within the Netrin-1 binding region but outside the binding interface (Fig. S9-186 
12) are consistent with in vitro studies demonstrating that even conservative mutations to residues 187 
in this binding region can disrupt DCC dimerization, Netrin-1 binding and axon guidance14. 188 
 189 
 - 8 - 
In addition to the effect of sex hormones and the type and location of DCC mutations, 190 
developmental differences between the CC and corticospinal tract may also contribute to the 191 
variable ACC/MM phenotypes. Callosal and sub-cerebrally projecting pyramidal neurons of the 192 
cortex are specified at early stages of development and the molecular identity of each population 193 
directly affects its axonal connectivity16. While corticospinal axons utilise DCC/Netrin-1 194 
signalling to reach the midline, callosal axons use DCC/Netrin-1 chemoattraction to attenuate 195 
ROBO1/SLIT-2-mediated chemorepulsion to approach and cross the midline17. Therefore, a 196 
DCC mutation may differentially affect commissural versus subcerebral axon trajectories, leading 197 
to ACC, MM or both. MM were consistently associated with reduced crossing of descending 198 
corticospinal tract projections at the pyramidal decussation in this study as well as in individuals 199 
with RAD51-related MM18, suggesting that DCC-mediated MM are primarily the result of 200 
corticospinal tract decussation abnormalities. 201 
 202 
In conclusion, our results provide compelling evidence that DCC mutations cause isolated ACC 203 
in humans, in addition to the previously-reported MM phenotype. The factors determining the 204 
phenotypic variability are complex and likely include the hormonal context during development, 205 
the type and location of DCC mutation, and the genetic background of the individual. Although 206 
the full spectrum of phenotypes associated with DCC mutations remains to be fully characterized, 207 
individuals described in this study have an intellectual quotient within the normal/borderline 208 
range. Heterozygous mutations in DCC therefore appear to result in isolated ACC with a mild 209 
phenotype and favorable cognitive outcomes, contrasting with the unfavourable developmental 210 
outcomes associated with syndromic ACC. Given the high frequency of DCC mutations detected 211 
in our cohorts, this observation has prenatal diagnostic and parental counselling implications for 212 
fetuses with ACC as the condition currently has unclear prognostication. Our data suggest that 213 
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the prenatal detection of isolated ACC related to a pathogenic DCC mutation indicates a lower 214 
risk of an abnormal neurodevelopmental outcome.  215 
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Figure legend  355 
Figure 1 DCC mutations cause isolated ACC and/or MM associated with significantly reduced 356 
crossing of descending corticospinal tract projections at the pyramidal decussation. 357 
a. All available family samples were analysed; m=mutation; black dot=mutation carrier; 358 
blue=partial ACC; black=complete ACC and grey=MM. * indicates neuroimaging data for 359 
mutation carrier or individual with MM. 360 
b. Midsagittal MRI of control and family proband/representative individual (1-2=complete ACC; 361 
3=near complete ACC with thin rostrum and genu remaining and 4=partial ACC with absence of 362 
the rostrum and genu). 363 
c. Group-wise comparison of laterality coefficient in both families (family 2, n=4; family 4, n=3) 364 
were compared to controls (n=6). For each individual, a laterality coefficient for the corticospinal 365 
tract was calculated as the ratio of the difference between the numbers of crossed and uncrossed 366 
streamlines to the total number of streamlines. Right and left coefficients were averaged to find 367 
the laterality coefficient of each individual. Greater positive values indicate more crossed and 368 
negative values more uncrossed streamlines (mean +/- S.D, * p=0.0238 ; ** p=0.0095; two-tailed 369 
Mann-Whitney U-test). 370 
d. Protein domain structure depicting the location of the DCC truncation (red square and triangle) 371 
and missense mutations (colored dots). The Netrin-1 binding region is indicated, IgC2, 372 
immunoglobulin-like type C2 domain; FN3, fibronectin type III-like domain; TM, 373 
transmembrane domain; P1-3, conserved motifs.  374 
0 
 
Table 1: Summary of DCC mutations identified in individuals with ACC (+/-MM) in this study. cACC, complete isolated agenesis of 375 
the corpus callosum; pACC, partial isolated agenesis of the corpus callosum; MM, mirror movements; IgC2, immunoglobulin-like type 376 
C2 domain; FN3, fibronectin type III-like domain; ExAC, Exome Aggregation Consortium; dbSNP, dbSNP reference SNP 377 
identification number. Reference sequences used are NM_005215.3 and NP_005206.2. 378 
Family 
number Phenotype cDNA  Protein 
Protein 
domain SIFT PolyPhen-2 ExAC dbSNP 
1 cACC or pACC ± MM c.925delA p.(Thr309ProfsTer26) IgC2-3 - - No - 
2 cACC & MM c.2378T>G p.(Val793Gly) FN3-4 Deleterious Probably damaging No - 
3 cACC or MM ± pACC c.823C>T p.(Arg275Ter) IgC2-3 - - No - 
4 pACC &/or MM c.2414G>A p.(Gly805Glu) FN3-4 Deleterious 
Probably 
damaging No - 
5 cACC c.1790G>C p.(Arg597Pro) FN3-2 Deleterious Probably damaging No - 
6 cACC c.2227A>T p.(Met743Leu) FN3-4 Deleterious Benign No rs199651452 
7 cACC c.2260G>A p.(Val754Met) FN3-4 Deleterious Possibly damaging Yes (x19) - 
8 cACC c.2677G>A p.(Ala893Thr) FN3-5 Deleterious Benign No - 
9 cACC c.3649A>G; c.3748G>A 
p.(Met1217Val); 
p.(Ala1250Thr) Cytoplasmic 
Tolerated; 
Tolerated 
Benign; 
Probably 
damaging 
No; Yes 
(x2) - 
  
